Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison
Journal of Comparative Effectiveness Research · 2026-07 · 15 (7)
DOI: 10.57264/cer-2026-0069 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Comparative Effectiveness Research, 2026-07. Verfasst von Handrean Soran und 12 weiteren Autor:innen. Beteiligte Einrichtung: NIHR/Welcome Trust Clinical Research Facility & Manchester University Hospital NHS Foundation Trust, Manchester, UK. Hauptthemen laut MEDLINE: Hyperlipoproteinemia Type I, Oligonucleotides, Hyperlipoproteinemia Type II. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Familial chylomicronemia syndrome (FCS) is a rare genetic disorder characterized by severe hypertriglyceridemia causing recurrent acute pancreatitis (AP). Since FCS is a genetic deficiency in functional lipoprotein lipase, conventional triglyceride-lowering therapies are ineffective in this metabolic disorder. Apolipoprotein C-III (apoC-III) inhibitors, including volanesorsen and olezarsen, have emerged as targeted treatments for FCS.
Aim
To compare the efficacy and safety of olezarsen 80 mg every four weeks (Q4W) versus volanesorsen 300 mg weekly (QW) in patients with FCS using an anchored matching-adjusted indirect comparison. Materials & methods: Individual patient data from the Balance trial of olezarsen (n = 45) were weighted to match baseline characteristics reported in the APPROACH trial of volanesorsen (n = 66). Outcomes included percent change in fasting triglycerides (TG) and apoC-III at 26 and 52 weeks, and risks of AP events and adverse events at 52 weeks.
Results
At 52 weeks, mean differences in fasting TG and apoC-III were -27.4% (95% CI: -69.4, 14.5) and -21.3% (95% CI: -61.9, 19.3). Relative risks of AP, treatment-emergent adverse events, and serious adverse events were 0.23 (95% CI: 0.01, 5.02), 0.87 (95% CI: 0.66, 1.13) and 0.50 (95% CI: 0.08, 3.26) at week 52. The rate ratio for AP events per patient-year was 0.06 (95% CI: 0.003, 1.41). No comparisons were statistically significant.
Conclusion
In this matching-adjusted indirect comparison, no statistically significant differences in outcomes were observed between olezarsen and volanesorsen in patients with FCS. These findings provide important comparative context in a setting where head-to-head evidence is unavailable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NIHR/Welcome Trust Clinical Research Facility & Manchester University Hospital NHS Foundation Trust, Manchester, UK.
- Ionis Pharmaceuticals Inc., Carlsbad, CA, USA.
- Evidinno Outcomes Research Inc., Vancouver, BC, Canada.
- Department of Endocrinology, ULS Sao Joao, Faculty of Medicine, University of Porto (FMUP), Porto, Portugal.
- Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands.
- Department of Internal Medicine III of the University Hospital Dresden, Technical University of Dresden, Germany.
ORCID-Profile: Asia Sikora Kessler, Montserrat Vera-Llonch, Veronica J Alexander, Paul Serafini, Divya Pushkarna, Erik Stroes, Ulrike Schatz, Ursula Kassner, Zalmai Hakimi, Koo Wilson
Zitieren
APA
Soran, H., Kessler, A. S., Vera-Llonch, M., Alexander, V. J., Serafini, P., Pushkarna, D., Rodrigues, E., Stroes, E., Schatz, U., Kassner, U., Hakimi, Z., Falk, A., & Wilson, K. (2026). Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison. Journal of Comparative Effectiveness Research, 15(7). https://doi.org/10.57264/cer-2026-0069
Vancouver
Soran H, Kessler AS, Vera-Llonch M, Alexander VJ, Serafini P, Pushkarna D, et al. Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison. Journal of Comparative Effectiveness Research. 2026;15(7). doi:10.57264/cer-2026-0069
BibTeX
@article{Soran2026,
author = {Soran, Handrean and Kessler, Asia Sikora and Vera-Llonch, Montserrat and Alexander, Veronica J and Serafini, Paul and Pushkarna, Divya and Rodrigues, Elisabete and Stroes, Erik and Schatz, Ulrike and Kassner, Ursula and Hakimi, Zalmai and Falk, Aletta and Wilson, Koo},
title = {Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison},
journal = {Journal of Comparative Effectiveness Research},
year = {2026},
volume = {15},
number = {7},
doi = {10.57264/cer-2026-0069}
}
EUVIMED